Minocycline Treatment for Cystoid Macular Edema

Efficacy and Safety of the Treatment of Minocycline for Cystoid Macular Edema

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05474950

Acronym

MINOCME

Enrollment

Registered

2022-07-26

Start date

2019-01-01

Completion date

2025-06-01

Last updated

2023-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystoid Macular Edema, Minocycline

Brief summary

Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.

Interventions

DRUGminocycline

minocycline capsule (100mg) per day orally

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Participant diagnosed with CME. * Participant aged from 18-60 years old. * Participant that signed the informed consent document and is able to complete the following visits.

Exclusion criteria

* Participant is allergy to minocycline or tetracyclines. * Participant has no contraindications of minocycline or tetracyclines. * Participant has an abnormal function of liver, heart, kidney and thyroid. * Female that is pregnant, breast-feeding or planning to become pregnant. * Participant that is currently using other medications.

Design outcomes

Primary

Measure	Time frame	Description
Change of cystoid macular edema	At 6 months	Change of CME measured by Optical coherence tomography (OCT)

Secondary

Measure	Time frame	Description
Change of best corrected visual acuity (BCVA)	At 6 months	Change of BCVA measured by the Early Treatment Diabetic Retinopathy Study
Change of macular sensitivity	At 6 months	Change of BCVA measured by Macular Integrity Assessment (MAIA)
Change of retinal vascular leakage	At 6 months	Change of retinal vascular leakage measured by Fundus fluorescein angiography (FFA) or indocyanine green angiography (ICGA)
Change of macular vessel	At 6 months	Change of macular vessel measured by optical coherence tomography angiography (OCTA)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026